famotidine has been researched along with 2019 Novel Coronavirus Disease in 37 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia." | 2.82 | Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. ( Mirsaeidi, M; Nasiri, MJ; Rommasi, F, 2022) |
| "Famotidine was reported to potentially provide benefits to Coronavirus Disease 2019 (COVID-19) patients." | 2.72 | Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis. ( Ayaz Ahmed, M; Bhan, C; Chen, Y; Guo, Z; Hu, L; Liang, M; Sun, C; Wu, Y; Yan, Y; Yang, H; Zhou, Q; Zuo, Y, 2021) |
| "Famotidine is a histamine-2 (H2) receptor antagonist which blocks the H2 receptors in the parietal cells, decreasing gastric acid secretion." | 2.72 | Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review. ( Chenchula, S; Ray, A; Sadasivam, B, 2021) |
| "Famotidine use was not associated with incidence of laboratory-confirmed (P= 0." | 1.91 | Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study. ( Alnouri, G; Balouch, B; Sataloff, RT; Vontela, S; Yeakel, H, 2023) |
| "The famotidine nonuser group was derived from the same source population with no history of exposure to any drug with famotidine as an active ingredient before or on the day of admission." | 1.62 | Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. ( Berlin, JA; Fortin, SP; Ryan, P; Shoaibi, A; Weinstein, R, 2021) |
| "Famotidine was well tolerated." | 1.56 | Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. ( Conigliaro, J; Gablenz, E; Janowitz, T; Pattinson, D; Tracey, K; Tuveson, D; Wang, TC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 37 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Dong, Y | 1 |
| Lei, X | 1 |
| Rommasi, F | 1 |
| Nasiri, MJ | 1 |
| Mirsaeidi, M | 1 |
| Yang, H | 2 |
| George, SJ | 1 |
| Thompson, DA | 1 |
| Silverman, HA | 1 |
| Tsaava, T | 1 |
| Tynan, A | 1 |
| Pavlov, VA | 1 |
| Chang, EH | 1 |
| Andersson, U | 1 |
| Brines, M | 1 |
| Chavan, SS | 1 |
| Tracey, KJ | 2 |
| Lin, KJ | 1 |
| Feldman, WB | 1 |
| Wang, SV | 1 |
| Pramod Umarje, S | 1 |
| D'Andrea, E | 1 |
| Tesfaye, H | 1 |
| Zabotka, LE | 1 |
| Liu, J | 1 |
| Desai, RJ | 1 |
| Cheema, HA | 3 |
| Shafiee, A | 3 |
| Athar, MMT | 3 |
| Shahid, A | 3 |
| Awan, RU | 3 |
| Afifi, AM | 3 |
| Shah, J | 3 |
| Jalal, PK | 3 |
| Tachoua, W | 1 |
| Kabrine, M | 1 |
| Mushtaq, M | 1 |
| Selmi, A | 1 |
| Ul-Haq, Z | 1 |
| Momtazmanesh, S | 1 |
| Ansari, S | 1 |
| Izadi, Z | 1 |
| Shobeiri, P | 1 |
| Vatankhah, V | 1 |
| Seifi, A | 1 |
| Ghiasvand, F | 1 |
| Bahrami, M | 1 |
| Salehi, M | 1 |
| Noorbala, AA | 1 |
| Akhondzadeh, S | 1 |
| Kow, CS | 2 |
| Ramachandram, DS | 1 |
| Hasan, SS | 2 |
| Durán-Álvarez, JC | 1 |
| Prado, B | 1 |
| Zanella, R | 1 |
| Rodríguez, M | 1 |
| Díaz, S | 1 |
| Freedberg, DE | 2 |
| Conigliaro, J | 2 |
| Wang, TC | 3 |
| Callahan, MV | 1 |
| Abrams, JA | 2 |
| Janowitz, T | 1 |
| Gablenz, E | 1 |
| Pattinson, D | 1 |
| Tracey, K | 1 |
| Tuveson, D | 1 |
| Sen Gupta, PS | 1 |
| Biswal, S | 1 |
| Singha, D | 1 |
| Rana, MK | 1 |
| Ortega, JT | 1 |
| Serrano, ML | 1 |
| Jastrzebska, B | 1 |
| Cheung, KS | 1 |
| Hung, IFN | 1 |
| Leung, WK | 1 |
| Ghosh, R | 1 |
| Chatterjee, S | 1 |
| Dubey, S | 1 |
| Lavie, CJ | 2 |
| Singh, VP | 1 |
| El-Kurdi, B | 1 |
| Rood, C | 1 |
| Mather, JF | 1 |
| Seip, RL | 1 |
| McKay, RG | 1 |
| Hogan Ii, RB | 1 |
| Hogan Iii, RB | 1 |
| Cannon, T | 1 |
| Rappai, M | 1 |
| Studdard, J | 1 |
| Paul, D | 1 |
| Dooley, TP | 1 |
| Grewal, E | 1 |
| Sutarjono, B | 1 |
| Mohammed, I | 1 |
| Samimagham, HR | 1 |
| Hassani Azad, M | 1 |
| Haddad, M | 1 |
| Arabi, M | 1 |
| Hooshyar, D | 1 |
| KazemiJahromi, M | 1 |
| Yeramaneni, S | 1 |
| Doshi, P | 1 |
| Sands, K | 1 |
| Cooper, M | 1 |
| Kurbegov, D | 1 |
| Fromell, G | 1 |
| Theoharides, TC | 1 |
| Zhou, J | 1 |
| Wang, X | 1 |
| Lee, S | 1 |
| Wu, WKK | 1 |
| Cheung, BMY | 1 |
| Zhang, Q | 1 |
| Tse, G | 1 |
| Sethia, R | 1 |
| Prasad, M | 1 |
| Garg, PK | 1 |
| Balouch, B | 1 |
| Vontela, S | 1 |
| Yeakel, H | 1 |
| Alnouri, G | 1 |
| Sataloff, RT | 1 |
| Kamal, F | 1 |
| Khan, MA | 1 |
| Sharma, S | 1 |
| Imam, Z | 1 |
| Howden, CW | 1 |
| Malone, RW | 1 |
| Sun, C | 1 |
| Chen, Y | 1 |
| Hu, L | 1 |
| Wu, Y | 1 |
| Liang, M | 1 |
| Ayaz Ahmed, M | 1 |
| Bhan, C | 1 |
| Guo, Z | 1 |
| Zuo, Y | 1 |
| Yan, Y | 1 |
| Zhou, Q | 1 |
| Loffredo, M | 1 |
| Lucero, H | 1 |
| Chen, DY | 1 |
| O'Connell, A | 1 |
| Bergqvist, S | 1 |
| Munawar, A | 1 |
| Bandara, A | 1 |
| De Graef, S | 1 |
| Weeks, SD | 1 |
| Douam, F | 1 |
| Saeed, M | 1 |
| Munawar, AH | 1 |
| Chenchula, S | 1 |
| Ray, A | 1 |
| Sadasivam, B | 1 |
| Abdul Sattar Burud, I | 1 |
| Shoaibi, A | 1 |
| Fortin, SP | 1 |
| Weinstein, R | 1 |
| Berlin, JA | 1 |
| Ryan, P | 1 |
| Ma, T | 1 |
| Wu, M | 1 |
| Mather, J | 1 |
| Amjad, W | 1 |
| Malik, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series[NCT04389567] | 10 participants (Actual) | Observational | 2020-05-12 | Completed | |||
| A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection[NCT06008860] | Phase 4 | 280 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Evaluation of a Synbiotic Formula in Patient With COVID-19[NCT04730284] | 20 participants (Anticipated) | Interventional | 2020-08-25 | Recruiting | |||
| A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19[NCT04724720] | Phase 2 | 56 participants (Actual) | Interventional | 2021-01-19 | Active, not recruiting | ||
| An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection[NCT04581018] | 50 participants (Anticipated) | Interventional | 2020-08-13 | Enrolling by invitation | |||
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients[NCT05077332] | Phase 2 | 2,000 participants (Anticipated) | Interventional | 2021-12-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for famotidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; COVID-19; COVID-19 Drug Treatment; | 2022 |
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Topics: COVID-19; Famotidine; Humans; SARS-CoV-2; Treatment Outcome | 2023 |
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Topics: COVID-19; Famotidine; Humans; SARS-CoV-2; Treatment Outcome | 2023 |
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Topics: COVID-19; Famotidine; Humans; SARS-CoV-2; Treatment Outcome | 2023 |
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Topics: COVID-19; Famotidine; Humans; SARS-CoV-2; Treatment Outcome | 2023 |
Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies.
Topics: COVID-19; Famotidine; Gastrointestinal Diseases; Humans; Observational Studies as Topic; Proton Pump | 2021 |
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.
Topics: COVID-19; COVID-19 Drug Treatment; Famotidine; Histamine H2 Antagonists; Humans; Intubation, Intratr | 2021 |
Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Topics: COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Evaluation, Preclinical; Drug Repositioning; Famo | 2021 |
2 trials available for famotidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study.
Topics: Cognition; COVID-19; Double-Blind Method; Famotidine; Histamine H2 Antagonists; Humans; Iran; Treatm | 2023 |
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
Topics: Betacoronavirus; Case-Control Studies; Clinical Protocols; Coronavirus Infections; COVID-19; Famotid | 2020 |
30 other studies available for famotidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews.
Topics: COVID-19; Famotidine; Humans; Propensity Score; SARS-CoV-2 | 2022 |
Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; COVID-19; Cytokine Relea | 2022 |
Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.
Topics: COVID-19; Famotidine; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2022 |
Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.
Topics: Antihypertensive Agents; COVID-19; COVID-19 Drug Treatment; Famotidine; Guanidines; Humans; Ligands; | 2023 |
Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment.
Topics: COVID-19; Famotidine; Humans; Mast Cells; SARS-CoV-2 | 2023 |
Wastewater surveillance of pharmaceuticals during the COVID-19 pandemic in Mexico City and the Mezquital Valley: A comprehensive environmental risk assessment.
Topics: Azithromycin; COVID-19; Dexamethasone; Environmental Monitoring; Famotidine; Humans; Ivermectin; Mex | 2023 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famotidine; | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Mon | 2020 |
Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.
Topics: COVID-19; Famotidine; Humans; Pharmaceutical Preparations; SARS-CoV-2 | 2021 |
Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.
Topics: Administration, Intravenous; Antiviral Agents; Computer Simulation; Coronavirus Infections; COVID-19 | 2020 |
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study.
Topics: COVID-19; Famotidine; Hong Kong; Humans; Propensity Score; Retrospective Studies; SARS-CoV-2 | 2021 |
Famotidine Against SARS-CoV2: A Hope or Hype?
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Famoti | 2020 |
What Underlies the Benefit of Famotidine Formulations Used During COVID-19?
Topics: COVID-19; Famotidine; Humans; Propensity Score; Retrospective Studies; SARS-CoV-2 | 2021 |
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Betacoronavirus; Cetirizine; Cohort Studies; Coronavirus | 2020 |
Angioedema, ACE inhibitor and COVID-19.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Benzazepines; Betacorona | 2020 |
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Famotidine; Hospital Mortality; Hospitalization | 2021 |
Potential association of mast cells with coronavirus disease 2019.
Topics: Cell Communication; Cholecalciferol; COVID-19; COVID-19 Drug Treatment; Cromolyn Sodium; Cyproheptad | 2021 |
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
Topics: COVID-19; Famotidine; Humans; Propensity Score; Proton Pump Inhibitors; SARS-CoV-2 | 2021 |
Famotidine and Coronavirus Disease 2019.
Topics: COVID-19; Famotidine; Histamine H2 Antagonists; Humans; SARS-CoV-2 | 2021 |
Famotidine and Mortality in Coronavirus Disease 2019.
Topics: COVID-19; Famotidine; Histamine H2 Antagonists; Humans; Retrospective Studies; SARS-CoV-2 | 2021 |
Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.
Topics: Adult; COVID-19; Famotidine; Gastroesophageal Reflux; Humans; Pilot Projects; SARS-CoV-2 | 2023 |
More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?
Topics: COVID-19; Famotidine; Gastroesophageal Reflux; Heartburn; Humans; SARS-CoV-2 | 2021 |
The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication.
Topics: A549 Cells; Animals; Chlorocebus aethiops; COVID-19; Famotidine; Humans; Peptide Hydrolases; SARS-Co | 2021 |
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
Topics: COVID-19; Famotidine; Histamine H2 Antagonists; Humans; RNA, Viral; SARS-CoV-2 | 2021 |
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
Topics: COVID-19; Famotidine; Histamine H2 Antagonists; Humans; RNA, Viral; SARS-CoV-2 | 2021 |
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Famot | 2021 |
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.
Topics: COVID-19; Famotidine; Histamine H2 Antagonists; Humans; Propensity Score; SARS-CoV-2 | 2021 |
Response to Ma and Wu.
Topics: COVID-19; Famotidine; Humans; SARS-CoV-2 | 2021 |
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?
Topics: COVID-19; Famotidine; Histamine H2 Antagonists; Humans; Retrospective Studies; SARS-CoV-2 | 2021 |